carbidopa/levodopa / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 61 Diseases   24 Trials   24 Trials   800 News 


12345678910111213...1314»
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Preclinical, Journal:  In Vivo Study of Moringa oleifera Seed Extracts as Potential Sources of Neuroprotection against Rotenone-Induced Neurotoxicity. (Pubmed Central) -  Jun 19, 2024   
    Sinemet-treated mice received 20 mg/kg, oral dose, as a positive group...A histological study showed reduced signs of neurodegeneration, vacuolation around multipolar cells and cytoplasmic shrinkage in MO extract-treated mice SN brain sections. Collectively, MO seed extracts protected the animals from locomotor deficits induced by rotenone, possibly through antioxidant means, and seem to have potential applications in neurodegenerative diseases.
  • ||||||||||  carbidopa/levodopa / Generic mfg., carbidopa / Generic mfg.
    Journal:  Dissolvable microarray patches of levodopa and carbidopa for Parkinson's disease management. (Pubmed Central) -  May 19, 2024   
    Biocompatibility assessments conducted on human dermal fibroblast cells corroborated acceptable cytocompatibility, confirming the suitability of these MAPs for dermal application. In conclusion, dissolving MAPs incorporating carbidopa and levodopa represent a promising alternative for improving the therapeutic management of Parkinson's disease.
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Journal:  Very Early Levodopa May Prevent Self-Injury in Lesch-Nyhan Disease. (Pubmed Central) -  May 19, 2024   
    Therefore, levodopa could be considered in patients with LND as early as possible, at least before the self-injury appears. Further research is needed to establish very early levodopa as an effective treatment strategy in LND, and to optimize timing and dosing.
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Trial termination:  Carbidopa-Levodopa in Dry AMD With Geographic Atrophy (clinicaltrials.gov) -  Apr 25, 2024   
    P2,  N=7, Terminated, 
    In addition, we document Active, not recruiting --> Terminated; Lack of funding required for enrollment to reach statistical significance.
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Journal:  Computer-aided optimization of carbidopa/levodopa orally disintegrating tablets. (Pubmed Central) -  Apr 22, 2024   
    The ODTs optimized using RSM and Python demonstrated excellent disintegration performance, leading to a decrease in the time the drug exists in solid form in the oral cavity. This improvement in disintegration time reduced the difficulty of swallowing for patients and enhanced medication compliance, while still ensuring that ODTs prepared by DC had sufficient mechanical strength to meet storage and transportation requirements.
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Preclinical, Journal:  Neuroprotective potential of Mentha piperita extract prevents motor dysfunctions in mouse model of Parkinson's disease through anti-oxidant capacities. (Pubmed Central) -  Apr 20, 2024   
    Swiss albino male mice were assigned to five groups: control (2.5% DMSO vehicle), PD (rotenone 2.5 mg/kg), EthMP and rotenone (200mg/kg and 2.5mg/kg, respectively), EthMP (200 mg/kg), and Sinemet, reference treatment containing levodopa and carbidopa (20 mg/kg and rotenone 2.5mg/kg)...Current data suggest therapeutic capacities of MP extract and neuroprotective capacities, possibly through antioxidant capacities. Therefore, it may have potential clinical applications for PD management.
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Journal:  Levodopa-Carbidopa: An Unusual Case of Voluntary Drug Intoxication (Pubmed Central) -  Apr 10, 2024   
    These results indicate that neither the addition of monophosphate prodrug moieties nor SC administration affects the circulating metabolite profile of foslevodopa/foscarbidopa compared to LCIG. No abstract available
  • ||||||||||  Trial completion date, Trial primary completion date:  The Role of Brain Dopamine in Chronic Pain (clinicaltrials.gov) -  Apr 4, 2024   
    P2,  N=10, Recruiting, 
    No abstract available Trial completion date: Apr 2024 --> Jan 2025 | Trial primary completion date: Apr 2024 --> Dec 2024
  • ||||||||||  Enrollment open, Trial completion date, Trial primary completion date:  Gait Analysis in Neurological Disease (clinicaltrials.gov) -  Apr 4, 2024   
    P=N/A,  N=120, Recruiting, 
    Trial completion date: Apr 2024 --> Jan 2025 | Trial primary completion date: Apr 2024 --> Dec 2024 Active, not recruiting --> Recruiting | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Intraputaminal AAV-CAv1.3-shRNA Averts Levodopa-induced Dyskinesias and Ameliorates Long-standing Parkinsonian Motor Deficits in Aged Parkinsonian Macaques (Colorado Convention Center | Mile High 4EF) -  Mar 8, 2024 - Abstract #AAN2024AAN_3859;    
    In these NHP studies, our primary outcome measure was the capacity of AAV-CaV1.3-shRNA to prevent LID induction in subjects exposed to twice-daily (M-Fr) carbidopa:levodopa (25:100 tablets) administered for 5.5 months using a dose escalation paradigm (20, 30, 40mg/kg). The therapeutic outcome of robust anti-dyskinetic efficacy together with the motor enhancing benefits, in the presence and absence of levodopa, when scaled up to a NHP model that displays many similarities with human PD, supports the strong promise of targeted (i.e., putaminal) CaV1.3 silencing for continued investigation and potential clinical development.
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Expounding a Rare Association Between Motor Neuron Disease and Parkinson-Plus Syndromes (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_3464;    
    The above cases should be evaluated further with medical genetics to determine relevant genes such as MAPT, C9-ORF-72, and progranulin. PPS may have properties of TDP-43 proteinopathy, suggesting a link to MND.
  • ||||||||||  Produodopa (foscarbidopa/foslevodopa) / AbbVie
    Effects of Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa on Sleep Dysfunction in People with Parkinson's (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_3190;    
    P3
    Participants had an overall positive experience and acceptability of using the LDp/CDp delivery system for their aPD treatment. These post hoc results demonstrate numerical improvement in two-of-three 12-week trial subdomains and TS in LDp/CDp versus oral (nominal P?.001), and significant within-group improvements in all three subdomains and TS of the 12- and 52-week LDp/CDp ITT populations, suggesting CSCI of LDp/CDp improves sleep in PwP.
  • ||||||||||  Produodopa (foscarbidopa/foslevodopa) / AbbVie
    Quality of Life Effects of Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa in People with Parkinson's (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_3188;    
    P3
    This post hoc analysis shows improvements in Mobility and Stigma versus the oral arm with a nominal P value of ?.05. And, the statistically significant within-group improvements versus baseline in four PDQ-39 subdomains of LDp/CDp-treated patients are consistent with the 52-week open-label trial results.
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Parkinson's Disease (PD) for the Primary Care Physician (PCP) (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_2499;    
    Increasing PCP comfort level in starting Sinemet trials on potential PD patients improves patient access to earlier PD treatment and having patients' response to a Sinemet trial helps the Neurologist with further assessment and treatment. Family Medicine residents' curriculum benefits from additional presentations to continually improve their comfort and knowledge of a wide array of neurological conditions.
  • ||||||||||  carbidopa/levodopa / Generic mfg., zolmitriptan / Generic mfg., dextromethorphan / Generic mfg.
    Journal:  Beneficial effect of 5-HT1b/1d agonist on Parkinson's disease by modulating glutamate and reducing deposition of ?-synuclein. (Pubmed Central) -  Jan 21, 2024   
    PD was induced in rats by reserpine at 5?mg/kg ip for 3 days and thereafter the rats were provided with the following treatments for 4 days, zolmitriptan (ZLM) group (30?mg/kg ip); STD group (levodopa?+?carbidopa, 200?+?5?mg/kg ip); ZLM?+?GA group (zolmitriptan, 30?mg/kg ip and glutamic acid, 1.5?mg/kg); ZLM?+?DX group (zolmitriptan, 30?mg/kg ip and dextromethorphan, 20?mg/kg ip). This study concludes by stating that
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Journal:  Levodopa/Carbidopa to Augment the Treatment of Amblyopia: A Report by the American Academy of Ophthalmology. (Pubmed Central) -  Jan 3, 2024   
    The best available evidence is currently insufficient to show that augmenting amblyopia therapy using up to 16 weeks of levodopa/carbidopa will result in meaningful improvement in visual acuity. Given the potential for significant side effects such as tardive dyskinesia with long-term therapy, levodopa/carbidopa does not appear to be a viable option for amblyopia therapy FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
  • ||||||||||  Trial completion date, Trial primary completion date:  Substance Abuse Pre-Treatment Screening Study (clinicaltrials.gov) -  Dec 20, 2023   
    P=N/A,  N=7500, Recruiting, 
    Given the potential for significant side effects such as tardive dyskinesia with long-term therapy, levodopa/carbidopa does not appear to be a viable option for amblyopia therapy FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Jun 2026
  • ||||||||||  Enrollment closed:  Dopaminergic Enhancement of Rehabilitation Therapy Early After Stroke (clinicaltrials.gov) -  Nov 30, 2023   
    P1/2,  N=72, Active, not recruiting, 
    Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Jun 2026 Recruiting --> Active, not recruiting
  • ||||||||||  carbidopa / Generic mfg.
    Journal:  Quantitative Colorimetric Sensing of Carbidopa in Anti-Parkinson Drugs Based on Selective Reaction with Indole-3-Carbaldehyde. (Pubmed Central) -  Nov 29, 2023   
    A filter-based plate reader was used for colorimetric data acquisition, providing superior results in terms of analytical performances for I3A, with a sensitivity ~50 L g and LOD ~0.1 mg L in comparison to a previous study based on vanillin, giving, for the same figures of merit values, about 13 L g and 0.2-0.3 mg L, respectively. The calibration curves for the standard solution and drugs were almost superimposable, therefore excluding interference from the excipients and additives, with very good reproducibility (RSD% 2-4%) within the linear dynamic range (10 mg L-50 mg L).
  • ||||||||||  Trivastal (piribedil) / Servier
    Retrospective data, Journal:  Comparison of the effectiveness, safety, and costs of anti-Parkinson drugs: A multiple-center retrospective study. (Pubmed Central) -  Nov 20, 2023   
    Concomitant use of MgO and levodopa should be discouraged to improve levodopa absorption. Carbidopa/levodopa or levodopa/benserazide might exhibit better clinical improvement with less medical cost, while piribedil presented less clinical improvement but a higher risk of headache/dizziness, gastrointestinal, and neuropsychiatric symptoms.
  • ||||||||||  carbidopa/levodopa / Generic mfg., cyclobenzaprine / Generic mfg., propranolol / Generic mfg.
    Parkinsonian Features After Elective Carotid Endarterectomy: A Case Report () -  Nov 16, 2023 - Abstract #AAPMR2023AAPMR_835;    
    The exact mechanism of action is unknown but maybe due to use of anesthetic agents or from stress of the surgery. Further research is required to determine the mechanism.
  • ||||||||||  carbidopa/levodopa / Generic mfg., amantadine / Generic mfg.
    A Rehabilitation Perspective on Fahr's Disease: A Case Report () -  Nov 16, 2023 - Abstract #AAPMR2023AAPMR_718;    
    Symptoms improved following establishment of sleep regimen, discontinuation of Amantadine, as well as optimization of Levodopa-Carbidopa. A multi-disciplinary approach to a comprehensive rehabilitation program can play an important role in managing the symptoms of Fahr's disease and improving patients' functional mobility and quality of life.
  • ||||||||||  carbidopa/levodopa / Generic mfg., levodopa/carbidopa orally disintegrating tablets / Generic mfg.
    Trial completion date, Trial primary completion date:  Vigor and the LDR in Parkinson Disease (clinicaltrials.gov) -  Nov 8, 2023   
    P=N/A,  N=40, Recruiting, 
    A long-acting dopamine agonist, such as cabergoline, may be a necessary adjunctive treatment for most patients with BH deficiency. Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    The influence of dopamine on afferent inhibition and corticospinal excitability (WCC Halls A-C) -  Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_7349;    
    In this placebo-controlled and double-anonymous study, Apo Levocarb (100mg levodopa/25mg carbidopa) and placebo were administered in two separate sessions to 32 right-handed males (mean age 24...Preliminary results indicate that SAI is modulated by dopaminergic medication. Further results are pending the completed gene analyses.
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  DTA (Dopaminergic Therapy for Anhedonia) Study (clinicaltrials.gov) -  Oct 25, 2023   
    P4,  N=20, Completed, 
    Oral suspensions of amoxicillin trihydrate (50 mg/mL), clozapine (25 mg/mL), indomethacin (5.0 mg/mL), levodopa/carbidopa (10.0/2.5 mg/mL), levothyroxine sodium (T4, 25 Recruiting --> Completed | N=35 --> 20 | Trial completion date: Nov 2025 --> Oct 2023 | Trial primary completion date: Nov 2025 --> Oct 2023
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  STIMO-PHARMA: Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES (clinicaltrials.gov) -  Oct 5, 2023   
    P1,  N=3, Completed, 
    The analgesic effect of carbidopa levodopa on patients with or without PD is worth studying in further research. Enrolling by invitation --> Completed | Trial completion date: May 2023 --> Oct 2023 | Trial primary completion date: May 2023 --> Oct 2023